|
1
|
Kleber M, Ntanasis-Stathopoulos I and
Terpos E: BCMA in multiple Myeloma-A promising key to therapy. J
Clin Med. 10:40882021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moreau P, Garfall AL, van de Donk NWCJ,
Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L,
Chari A, et al: Teclistamab in relapsed or refractory multiple
myeloma. N Engl J Med. 387:495–505. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dimopoulos MA, Merlini G, Bridoux F, Leung
N, Mikhael J, Harrison SJ, Kastritis E, Garderet L, Gozzetti A, van
de Donk NWCJ, et al: Management of multiple myeloma-related renal
impairment: Recommendations from the International Myeloma Working
Group. Lancet Oncol. 24:e293–e311. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ryman JT and Meibohm B: Pharmacokinetics
of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol.
6:576–588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mohan M, Monge J, Shah N, Luan D, Forsberg
M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani
D, et al: Teclistamab in relapsed refractory multiple myeloma:
Multi-institutional real-world study. Blood Cancer J. 14:352024.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sandahl TB, Soefje SA, Fonseca R,
Ailawadhi S, Parrondo R, Lin D, Wu B, Calay ES, Silvert E, Kim N,
et al: Real-world safety and health care resource utilization of
teclistamab under an outpatient model for Step-Up dosing
administration. JCO Oncol Pract. 21:702–709. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gordon B, Fogel L, Varma G, Saldarriaga
MM, Ahn J, Aleman A, Caro J, Chen X, Monge J, Parmar H, et al:
Teclistamab demonstrates clinical activity in Real-world patients
ineligible for the pivotal Majestec-1 trial. Blood. 142:4741. 2023.
View Article : Google Scholar
|
|
8
|
Dima D, Davis JA, Ahmed N, Jia X,
Sannareddy A, Shaikh H, Shune L, Kaur G, Khouri J, Afrough A, et
al: Safety and efficacy of teclistamab in patients with
Relapsed/Refractory multiple myeloma: A real-world experience.
Transplant Cell Ther. 30:308.e132024.PubMed/NCBI
|
|
9
|
Tan CR, Asoori S, Huang CY, Brunaldi L,
Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM,
Chhabra S, et al: Real-world evaluation of teclistamab for the
treatment of relapsed/refractory multiple myeloma (RRMM): An
International Myeloma Working Group study. Blood Cancer J.
15:532025. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Charkviani M, Brochero MJV, Mohan A,
Vaughan LE, Sandahl TB, De Menezes Silva Corrae A, Lin Y, Leung N
and Herrmann SM: Incidence of acute kidney injury in relapsed and
refractory multiple myeloma treated with teclistamab versus CAR
T-cells. Nephrol Dial Transplant. gfaf0042025.doi:
10.1093/ndt/gfaf004 (Epub ahead of print). PubMed/NCBI
|
|
11
|
Khouderchah CJ, Ochs M, Pianko M,
Mahmoudjafari Z, Snyder J, Ahmed I, Campagnaro E and Nachar VR:
Administration of teclistamab in four patients with multiple
myeloma requiring hemodialysis. J Oncol Pharm Pract. 30:1089–1095.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Joiner L, Bal S, Godby KN and Costa LJ:
Teclistamab in patients with multiple myeloma and impaired renal
function. Am J Hematol. 98:E322–E324. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lebreton P, Lachenal F, Bouillie S, Pica
GM, Aftisse H, Pascal L, Montes L, Macro M, Johnson N, Harel S, et
al: Teclistamab for relapsed refractory multiple myeloma patients
on dialysis. Br J Haematol. 205:2077–2079. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Riedhammer C, Bassermann F, Besemer B,
Bewarder M, Brunner F, Carpinteiro A, Einsele H, Faltin J, Frenking
J, Gezer D, et al: Real-world analysis of teclistamab in 123 RRMM
patients from Germany. Leukemia. 38:365–371. 2024. View Article : Google Scholar : PubMed/NCBI
|
